adipose tissue
• body fat content is higher in 2 and 3 month old mice
• treatment with the brain-penetrant glucosylceramide synthase inhibitor Genz-667161 attenuates the weight and body fat differences up to 6 months of age
|
• adipocytes exhibit greater heterogeneity and are larger
• Genz-667161 treatment normalizes adipocyte size
|
behavior/neurological
polyphagia
(
J:296033
)
• mice are hyperphagic
• Genz-667161 treatment reduces food consumption
|
cellular
• loss of hypothalamic primary cilia
• Genz-667161 treatment reduces the loss of hypothalamic cilia
|
• mice exhibit reduced cilia in the main olfactory epithelium
|
craniofacial
• mice show an accumulation of Dcx+ immature neurons at the expense of OMP+ mature neurons in the main olfactory epithelium
• Genz-667161 treatment preserves the cellular composition of the main olfactory epithelium
|
• mice exhibit reduced cilia in the main olfactory epithelium
|
growth/size/body
• mice show an accumulation of Dcx+ immature neurons at the expense of OMP+ mature neurons in the main olfactory epithelium
• Genz-667161 treatment preserves the cellular composition of the main olfactory epithelium
|
• mice exhibit reduced cilia in the main olfactory epithelium
|
• mice are smaller at birth but the difference is no longer seen at 2 months of age
|
• 3 month old mice are heavier and develop obesity
• treatment with Genz-667161 attenuates the weight and body fat differences up to 6 months of age
|
• increase in liver weight
• Genz-667161 treatment normalizes liver weight
|
homeostasis/metabolism
• increase in serum leptin levels
• Genz-667161 treatment reduces serum leptin levels
|
• triglyceride levels are significantly increased albeit within normal range
• Genz-667161 treatment reduces triglyceride levels to wild-type levels
|
• serum alanine transaminase levels are significantly increased albeit within normal range
• Genz-667161 treatment reduces serum alanine transaminase levels to wild-type levels
|
• mice show increased glucosylceramide levels in serum
• Genz-667161 treatment reduces levels of glucosylceramide in the serum
|
liver/biliary system
• increase in liver weight
• Genz-667161 treatment normalizes liver weight
|
nervous system
respiratory system
• mice show an accumulation of Dcx+ immature neurons at the expense of OMP+ mature neurons in the main olfactory epithelium
• Genz-667161 treatment preserves the cellular composition of the main olfactory epithelium
|
• mice exhibit reduced cilia in the main olfactory epithelium
|
taste/olfaction
• mice show an accumulation of Dcx+ immature neurons at the expense of OMP+ mature neurons in the main olfactory epithelium
• Genz-667161 treatment preserves the cellular composition of the main olfactory epithelium
|
• mice exhibit reduced cilia in the main olfactory epithelium
|
• mice exhibit up to a 5-fold increase in latency time to find a buried treat indicating anosmia
• Genz-667161 treatment corrects the anosmia
|
vision/eye
• outer nuclear layer is thinner in 4-week old mice with a more pronounced difference at 6 months of age
• Genz-667161 treatment results in an approximate 2-fold increase in the thickness of the outer nuclear layer
|
• mice show early-onset severe degeneration of the outer nuclear layer
|
renal/urinary system
N |
• mice exhibit normal kidney pathology
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
Bardet-Biedl syndrome 2 | DOID:0110124 |
OMIM:615981 |
J:296033 |